nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—Red blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.0575	0.0603	CcSEcCtD
Sitaxentan—Pneumonia aspiration—Riluzole—amyotrophic lateral sclerosis	0.0304	0.0318	CcSEcCtD
Sitaxentan—Panophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0272	0.0285	CcSEcCtD
Sitaxentan—Alveolitis allergic—Riluzole—amyotrophic lateral sclerosis	0.0254	0.0266	CcSEcCtD
Sitaxentan—Uterine leiomyoma—Riluzole—amyotrophic lateral sclerosis	0.0254	0.0266	CcSEcCtD
Sitaxentan—Cardiac murmur—Riluzole—amyotrophic lateral sclerosis	0.0214	0.0224	CcSEcCtD
Sitaxentan—Facial paralysis—Riluzole—amyotrophic lateral sclerosis	0.0209	0.0218	CcSEcCtD
Sitaxentan—Haematocrit decreased—Riluzole—amyotrophic lateral sclerosis	0.0178	0.0186	CcSEcCtD
Sitaxentan—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.0162	0.0169	CcSEcCtD
Sitaxentan—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.0141	0.0148	CcSEcCtD
Sitaxentan—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.0141	0.0148	CcSEcCtD
Sitaxentan—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0139	0.0146	CcSEcCtD
Sitaxentan—Tongue discolouration—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0144	CcSEcCtD
Sitaxentan—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.0135	0.0142	CcSEcCtD
Sitaxentan—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.0133	0.014	CcSEcCtD
Sitaxentan—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.0133	0.014	CcSEcCtD
Sitaxentan—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.0131	0.0138	CcSEcCtD
Sitaxentan—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0127	CcSEcCtD
Sitaxentan—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0127	CcSEcCtD
Sitaxentan—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0122	CcSEcCtD
Sitaxentan—Polyp—Riluzole—amyotrophic lateral sclerosis	0.0109	0.0114	CcSEcCtD
Sitaxentan—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0111	CcSEcCtD
Sitaxentan—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0109	CcSEcCtD
Sitaxentan—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0109	CcSEcCtD
Sitaxentan—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0106	CcSEcCtD
Sitaxentan—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00992	0.0104	CcSEcCtD
Sitaxentan—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00964	0.0101	CcSEcCtD
Sitaxentan—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00964	0.0101	CcSEcCtD
Sitaxentan—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00929	0.00973	CcSEcCtD
Sitaxentan—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00896	0.00939	CcSEcCtD
Sitaxentan—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00866	0.00907	CcSEcCtD
Sitaxentan—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00852	0.00892	CcSEcCtD
Sitaxentan—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00838	0.00878	CcSEcCtD
Sitaxentan—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00806	0.00844	CcSEcCtD
Sitaxentan—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.008	0.00838	CcSEcCtD
Sitaxentan—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.0076	0.00796	CcSEcCtD
Sitaxentan—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00755	0.00791	CcSEcCtD
Sitaxentan—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00739	0.00774	CcSEcCtD
Sitaxentan—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00734	0.00769	CcSEcCtD
Sitaxentan—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00729	0.00764	CcSEcCtD
Sitaxentan—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00725	0.00759	CcSEcCtD
Sitaxentan—Gout—Riluzole—amyotrophic lateral sclerosis	0.0071	0.00744	CcSEcCtD
Sitaxentan—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00701	0.00734	CcSEcCtD
Sitaxentan—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00701	0.00734	CcSEcCtD
Sitaxentan—EDNRB—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.00692	0.153	CbGpPWpGaD
Sitaxentan—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00675	0.00707	CcSEcCtD
Sitaxentan—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00663	0.00695	CcSEcCtD
Sitaxentan—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00663	0.00695	CcSEcCtD
Sitaxentan—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00663	0.00695	CcSEcCtD
Sitaxentan—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00656	0.00687	CcSEcCtD
Sitaxentan—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00633	0.00663	CcSEcCtD
Sitaxentan—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.0063	0.0066	CcSEcCtD
Sitaxentan—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00623	0.00652	CcSEcCtD
Sitaxentan—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.006	0.00628	CcSEcCtD
Sitaxentan—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00576	0.00603	CcSEcCtD
Sitaxentan—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00564	0.00591	CcSEcCtD
Sitaxentan—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00538	0.00564	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00531	0.00556	CcSEcCtD
Sitaxentan—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00512	0.00537	CcSEcCtD
Sitaxentan—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00495	0.00519	CcSEcCtD
Sitaxentan—EDNRA—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.00495	0.109	CbGpPWpGaD
Sitaxentan—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00493	0.00517	CcSEcCtD
Sitaxentan—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00481	0.00504	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00481	0.00504	CcSEcCtD
Sitaxentan—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00474	0.00496	CcSEcCtD
Sitaxentan—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00453	0.00474	CcSEcCtD
Sitaxentan—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00448	0.00469	CcSEcCtD
Sitaxentan—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00445	0.00466	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0044	0.00461	CcSEcCtD
Sitaxentan—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00435	0.00456	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00434	0.00454	CcSEcCtD
Sitaxentan—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00425	0.00445	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00425	0.00445	CcSEcCtD
Sitaxentan—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00416	0.00436	CcSEcCtD
Sitaxentan—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00405	0.00425	CcSEcCtD
Sitaxentan—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.004	0.00419	CcSEcCtD
Sitaxentan—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00399	0.00418	CcSEcCtD
Sitaxentan—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00395	0.00414	CcSEcCtD
Sitaxentan—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00389	0.00408	CcSEcCtD
Sitaxentan—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00384	0.00403	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.0038	0.00398	CcSEcCtD
Sitaxentan—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00394	CcSEcCtD
Sitaxentan—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00371	0.00389	CcSEcCtD
Sitaxentan—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00371	0.00389	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00366	0.00383	CcSEcCtD
Sitaxentan—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00364	0.00381	CcSEcCtD
Sitaxentan—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00379	CcSEcCtD
Sitaxentan—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00379	CcSEcCtD
Sitaxentan—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00371	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00368	CcSEcCtD
Sitaxentan—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.0035	0.00367	CcSEcCtD
Sitaxentan—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00348	0.00365	CcSEcCtD
Sitaxentan—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00355	CcSEcCtD
Sitaxentan—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00335	0.00351	CcSEcCtD
Sitaxentan—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00334	0.0035	CcSEcCtD
Sitaxentan—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00333	0.00349	CcSEcCtD
Sitaxentan—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00333	0.00349	CcSEcCtD
Sitaxentan—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00345	CcSEcCtD
Sitaxentan—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00328	0.00344	CcSEcCtD
Sitaxentan—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00327	0.00342	CcSEcCtD
Sitaxentan—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00311	0.00326	CcSEcCtD
Sitaxentan—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00324	CcSEcCtD
Sitaxentan—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00302	0.00317	CcSEcCtD
Sitaxentan—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00315	CcSEcCtD
Sitaxentan—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.003	0.00314	CcSEcCtD
Sitaxentan—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00308	CcSEcCtD
Sitaxentan—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00292	0.00306	CcSEcCtD
Sitaxentan—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.0029	0.00304	CcSEcCtD
Sitaxentan—Tension—Riluzole—amyotrophic lateral sclerosis	0.00285	0.00298	CcSEcCtD
Sitaxentan—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00295	CcSEcCtD
Sitaxentan—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00292	CcSEcCtD
Sitaxentan—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00272	0.00285	CcSEcCtD
Sitaxentan—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00269	0.00282	CcSEcCtD
Sitaxentan—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00268	0.00281	CcSEcCtD
Sitaxentan—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00279	CcSEcCtD
Sitaxentan—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00261	0.00274	CcSEcCtD
Sitaxentan—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00261	0.00273	CcSEcCtD
Sitaxentan—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00272	CcSEcCtD
Sitaxentan—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00259	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00257	CcSEcCtD
Sitaxentan—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00255	CcSEcCtD
Sitaxentan—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00253	CcSEcCtD
Sitaxentan—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00239	0.0025	CcSEcCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00238	0.0525	CbGpPWpGaD
Sitaxentan—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00248	CcSEcCtD
Sitaxentan—Infection—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00246	CcSEcCtD
Sitaxentan—EDNRB—Peptide GPCRs—C5AR1—amyotrophic lateral sclerosis	0.00234	0.0517	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00243	CcSEcCtD
Sitaxentan—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00243	CcSEcCtD
Sitaxentan—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00242	CcSEcCtD
Sitaxentan—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00241	CcSEcCtD
Sitaxentan—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00236	CcSEcCtD
Sitaxentan—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00232	CcSEcCtD
Sitaxentan—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00224	CcSEcCtD
Sitaxentan—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.0021	0.0022	CcSEcCtD
Sitaxentan—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00218	CcSEcCtD
Sitaxentan—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00215	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00214	CcSEcCtD
Sitaxentan—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00214	CcSEcCtD
Sitaxentan—Pain—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00212	CcSEcCtD
Sitaxentan—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00212	CcSEcCtD
Sitaxentan—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00204	CcSEcCtD
Sitaxentan—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00197	CcSEcCtD
Sitaxentan—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00196	CcSEcCtD
Sitaxentan—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00183	CcSEcCtD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.0017	0.0376	CbGpPWpGaD
Sitaxentan—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00178	CcSEcCtD
Sitaxentan—EDNRA—Peptide GPCRs—C5AR1—amyotrophic lateral sclerosis	0.00167	0.037	CbGpPWpGaD
Sitaxentan—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00162	0.0017	CcSEcCtD
Sitaxentan—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00164	CcSEcCtD
Sitaxentan—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00158	CcSEcCtD
Sitaxentan—Rash—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00156	CcSEcCtD
Sitaxentan—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00156	CcSEcCtD
Sitaxentan—Headache—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00155	CcSEcCtD
Sitaxentan—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00147	CcSEcCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00134	0.0296	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—PLA2G4A—amyotrophic lateral sclerosis	0.00131	0.029	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.0013	0.0286	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.00128	0.0282	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.0011	0.0243	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.000959	0.0212	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—PLA2G4A—amyotrophic lateral sclerosis	0.000939	0.0208	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000848	0.0188	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.000786	0.0174	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000737	0.0163	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000561	0.0124	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000559	0.0124	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000527	0.0117	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.00048	0.0106	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000402	0.00888	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000343	0.00759	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000339	0.0075	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000322	0.00711	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000317	0.00701	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000288	0.00637	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000267	0.0059	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000245	0.00542	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000243	0.00538	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000241	0.00534	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.00023	0.00509	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000227	0.00502	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000224	0.00497	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00022	0.00487	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000211	0.00467	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000206	0.00456	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.0002	0.00443	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000194	0.00429	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000186	0.00411	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000175	0.00388	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000172	0.00381	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.00017	0.00376	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00017	0.00376	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000169	0.00375	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000161	0.00355	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000158	0.00349	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000155	0.00343	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000151	0.00334	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.00015	0.00332	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000149	0.00329	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000145	0.00321	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000144	0.00319	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000143	0.00317	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000142	0.00315	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000139	0.00307	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000138	0.00306	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000137	0.00303	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000135	0.003	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000126	0.00278	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000123	0.00272	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000122	0.00269	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000117	0.00259	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.00011	0.00242	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000108	0.00239	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000107	0.00236	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000104	0.00231	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000102	0.00225	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000102	0.00225	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	9.91e-05	0.00219	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.85e-05	0.00218	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9.71e-05	0.00215	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	9.28e-05	0.00205	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—C3—amyotrophic lateral sclerosis	9e-05	0.00199	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.94e-05	0.00198	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.4e-05	0.00186	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.37e-05	0.00185	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	8.27e-05	0.00183	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	8.27e-05	0.00183	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.85e-05	0.00174	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.72e-05	0.00171	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	7.57e-05	0.00167	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	7.55e-05	0.00167	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	7.55e-05	0.00167	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.47e-05	0.00165	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.43e-05	0.00164	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.04e-05	0.00156	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.03e-05	0.00156	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.91e-05	0.00153	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	6.9e-05	0.00153	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	6.62e-05	0.00146	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.49e-05	0.00144	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.42e-05	0.00142	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.4e-05	0.00142	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.4e-05	0.00141	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	6.03e-05	0.00133	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.01e-05	0.00133	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	5.98e-05	0.00132	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.71e-05	0.00126	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	5.45e-05	0.00121	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.32e-05	0.00118	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	4.98e-05	0.0011	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	4.98e-05	0.0011	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.95e-05	0.00109	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	4.55e-05	0.00101	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	4.53e-05	0.001	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.4e-05	0.000973	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.23e-05	0.000936	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	4.18e-05	0.000925	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.16e-05	0.000919	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	4.13e-05	0.000914	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.09e-05	0.000904	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	3.98e-05	0.00088	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	3.82e-05	0.000844	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.81e-05	0.000843	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.73e-05	0.000825	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	3.6e-05	0.000796	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.47e-05	0.000768	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	3.44e-05	0.00076	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.15e-05	0.000696	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.14e-05	0.000693	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	3.13e-05	0.000693	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.97e-05	0.000658	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.86e-05	0.000632	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.82e-05	0.000624	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.73e-05	0.000603	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.67e-05	0.000591	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	2.52e-05	0.000557	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.15e-05	0.000475	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.07e-05	0.000457	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.02e-05	0.000446	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.96e-05	0.000433	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.85e-05	0.000408	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.7e-05	0.000375	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.68e-05	0.000372	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.55e-05	0.000342	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	1.4e-05	0.000309	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.27e-05	0.000282	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.11e-05	0.000246	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.02e-05	0.000226	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.57e-06	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.72e-06	0.000193	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	8.4e-06	0.000186	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.75e-06	0.000127	CbGpPWpGaD
